Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medistem Laboratories has entered into a licensing agreement with TriCell, an Indian biotechnology company specializing in stem cell banking, and research in the areas of hematological and oncological disorders.
Subscribe to our email newsletter
Under the terms of the agreement, which is subject to Indian government approval, Medistem Laboratories will receive cash and equity in TriCell. TriCell will receive access to Medistem’s intellectual property portfolio along with its know-how in the area of stem cell culturing and expansion for use in India and certain jurisdictions.
Thomas Ichim, CEO of Medistem, said: “This transaction positions Medistem to derive value from its IP assets while establishing a powerful collaborative base in India. TriCell’s access to significant medical facilities including a multi-specialty hospital that treats 3,000 patients daily provides a possible venue for performance of GCP-trials on Medistem’s various pipeline candidates.”